

### REMARKS

Claims 1, 5-7, 12-14, 18-21, 25, 28-30, 36-37 and 48 were previously pending in this application. Claims 6 and 29 have been cancelled. Claims 1, 5, 7, 28, 30, and 37 have been amended. Claims 1, 5, 7, 28, and 30 have been amended to recite that the dendritic cells are transfected with a nucleic acid molecule which encodes an E/L-selectin chimera or are genetically modified to express an E/L-selectin chimera. Support for the amendment can be found at least in Example 3 of the specification as filed. In addition, claim 37 has been amended to recite that the dendritic cells have been loaded with or transfected to express antigen. Support for the amendment can be found in the claims as originally filed. No new matter has been added.

### Rejection Under 35 U.S.C. § 112

The Examiner maintained the rejection of claims 1, 5-7, 12-14, 18-21, 25, 28-30, 36-37 and 48 under 35 U.S.C. §112, first paragraph, as not enabled. Claims 1, 5, 7, 28, 30, and 37 have been amended to overcome this rejection.

The Examiner has indicated that the claims as previously presented lacked enablement for “targeting dendritic cells to lymphoid or non-lymphoid tissues which express a selectin ligand by transfecting the dendritic cells with an expression vector encoding any selectin other than an E/L-selectin chimera which contains the transmembrane and intracellular domains of L-selectin and the extracellular domain of E-selection.” (Advisory Action mailed 10/24/2003). Applicant has amended the claims to specifically address the Examiner’s concerns. The amended claims now recite dendritic cells transfected with a nucleic acid molecule which encodes an E/L-selectin chimera or genetically modified to express an E/L-selectin chimera.

In addition, the Examiner indicated a lack of enablement for “generating therapeutic or antigen-specific immune responses *in vivo* wherein the dendritic cells have not been pulsed with or transfected to express antigen.” (Advisory Action mailed 10/24/2003). To address the Examiner’s concern, Applicant has amended claim 37 to recite that the dendritic cells are loaded with or transfected to express antigen.


Applicant believes that the amendments to the claims obviate the grounds for the Examiner’s rejections. Accordingly, Applicants respectfully request the withdrawal of the rejection of claims 1, 5-7, 12-14, 18-21, 25, 28-30, 36-37 and 48 under 35 U.S.C. §112, first paragraph.

**CONCLUSION**

In view of the foregoing amendments and remarks, this application should now be in condition for allowance. A notice to this effect is respectfully requested. If the Examiner believes, after this amendment, that the application is not in condition for allowance, the Examiner is requested to call the Applicant's attorney at the telephone number listed below.

If this response is not considered timely filed and if a request for an extension of time is otherwise absent, Applicant hereby requests any necessary extension of time. If there is a fee occasioned by this response, including an extension fee that is not covered by an enclosed check, please charge any deficiency to Deposit Account No. 23/2825.

Respectfully submitted,  
*Thomas S. Kupper et al., Applicant*

By:   
John R. Van Amsterdam, Reg. No. 40,212  
Wolf, Greenfield & Sacks, P.C.  
600 Atlantic Avenue  
Boston, Massachusetts 02210-2211  
Telephone: (617) 720-3500

Docket No. B0801.70170US00  
Date: March 11, 2004  
x03/11/04